Study wrapper · #772
Semaglutide Injection Once-Weekly for Weight Management in Adults: Results From A Randomized Phase III, Active-Controlled Study.
Editor's note
A 24-week randomised Phase III non-inferiority trial (270 adults with obesity or overweight plus a comorbidity, 21 Indian centres) compared a synthetic 'test' semaglutide against reference Wegovy for weight management. Researchers reported mean weight change of -13.8% (test) versus -14.1% (reference), a difference of 0.26% with a confidence interval well inside the non-inferiority margin, meaning the two performed comparably. Proportions reaching at least 5% and 10% loss were similar, as were BMI, waist, quality-of-life and glycaemic changes. Gastrointestinal events were the most common adverse events in both arms. This is solid randomised evidence for biosimilar-style equivalence rather than a novel efficacy claim, and the population and 24-week horizon are its main limits. For readers, it speaks to the growing supply of semaglutide products and whether alternatives match the reference in short-term weight outcomes.
Plain-language abstract
This randomised trial tested whether a newly made version of semaglutide works as well as the branded product Wegovy for weight loss. In India, 270 adults with obesity (or overweight plus a condition like high blood pressure, abnormal cholesterol, or type 2 diabetes) were randomly assigned to the test version or the reference version, given as a weekly injection under the skin with the dose gradually raised to 2.4 mg. After 24 weeks, both groups lost a similar amount of weight, about 14%, and the small difference between them was within the pre-set range for being considered equivalent. Similar shares of people lost at least 5% and 10% of their weight. Stomach and gut side effects were the most common in both groups. The main limits are the short 24-week window and the single-country setting.